US experts: OTC weight loss drug offers benefits (Reuters)


<p><a href="http://us.rd.yahoo.com/dailynews/rss/health/*http://news.yahoo.com/s/nm/20060124/hl_nm/obesity_dc"><img src="http://us.news3.yimg.com/us.i2.yimg.com/p/nm/20060124/2006_01_16t001518_450x284_us_obesity.jpg?x=130&y=82&sig=oAvJEYEIh1O1RQVQnPhWxg--" align="left" height="82" width="130" alt="An overweight pedestrian sits on a wall outside the Houses of Parliament in London in this March 31, 2004 file photo. A compound switching off the same brain circuits that make people hungry when they smoke cannabis looks set to become the world's first blockbuster anti-obesity medicine, with sales tipped by analysts to top $3 billion a year. Sanofi-Aventis SA's Acomplia, or rimonabant, which could be approved by U.S. regulators as early as next month, is the first of a new wave of treatments that may spell fat profits for some pharmaceutical companies. To match feature Health-Obesity. (Toby Melville/Files/Reuters)" border="0" /></a>Reuters - The first diet drug aimed at
helping the growing number of fat Americans lose weight without
seeing a doctor moved one step closer to U.S. approval on
Monday after a health advisory panel endorsed the idea.</p><br clear=all>